No­var­tis’ on­col­o­gy re­search chief in Chi­na jumps to up­start EpimAb in Shang­hai

Chi­na up­start EpimAb Bio­ther­a­peu­tics has wooed in a top re­searcher from No­var­tis as its first chief med­ical of­fi­cer.

Bin Peng, who had been glob­al chief of on­col­o­gy trans­la­tion­al med­i­cine at NI­BR’s Shang­hai group, is jump­ing to the start­up, which grabbed a $25 mil­lion launch round last April and is al­lied with not­ed UK an­ti­body de­sign shop Kymab. They have a lead drug — EMB01 — now head­ed in­to the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER